Evaxion AS (EVAX)
3.07
+0.09
(+3.02%)
USD |
NASDAQ |
Sep 02, 16:00
3.00
-0.07
(-2.28%)
After-Hours: 06:42
Evaxion Research and Development Expense (Annual) : 9.691M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 9.691M |
| December 31, 2024 | 10.14M |
| December 31, 2023 | 11.59M |
| December 31, 2022 | 16.62M |
| Date | Value |
|---|---|
| December 31, 2021 | 19.48M |
| December 31, 2020 | 10.88M |
| December 31, 2019 | 8.649M |
| December 31, 2018 | 4.266M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Autolus Therapeutics Plc | 128.59M |
| Cellectis SA | 75.08M |
| Akari Therapeutics Plc | 2.822M |
| DBV Technologies SA | 107.12M |
| argenx SE | 1.356B |